Format

Send to

Choose Destination
Clin Lymphoma Myeloma. 2006 Jul;7(1):26-9.

The role of thalidomide in multiple myeloma.

Author information

1
CIG Media Group, LP, Dallas, TX 75219, USA. chris.schwab@cigjournals.com

Abstract

Thalidomide has been demonstrated to be active as a first-line and salvage therapy in patients with multiple myeloma. Numerous studies over the past 8 years have shown it to induce high response rates and improve event-free survival in newly diagnosed patients as well as those with relapsed/refractory disease. Recent randomized clinical trials have demonstrated that thalidomide-based regimens are superior to conventional treatments in terms of response rates and event-free survival. However, few trials have demonstrated a survival benefit with thalidomide, indicating the need for further trials. This review will focus on recent trials of thalidomide in relapsed/refractory and newly diagnosed multiple myeloma and address some of the common adverse events associated with thalidomide treatment.

PMID:
16879766
DOI:
10.3816/CLM.2006.n.035
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center